Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(100.0%)
USD 0.0
(100.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 12.51 Million USD | 107.89% |
| 2021 | 6.02 Million USD | 5.41% |
| 2020 | 5.71 Million USD | 13.5% |
| 2019 | 5.03 Million USD | 9.13% |
| 2018 | 4.61 Million USD | -47.2% |
| 2017 | 8.73 Million USD | -89.1% |
| 2016 | 80.12 Million USD | 16.46% |
| 2015 | 68.8 Million USD | 64.9% |
| 2014 | 41.72 Million USD | -5.87% |
| 2013 | 44.32 Million USD | 231.34% |
| 2012 | 13.37 Million USD | 32.95% |
| 2011 | 10.06 Million USD | 49.49% |
| 2010 | 6.73 Million USD | -64.36% |
| 2009 | 18.88 Million USD | 95.82% |
| 2008 | 9.64 Million USD | -12.37% |
| 2007 | 11 Million USD | 32.11% |
| 2006 | 8.33 Million USD | 10.3% |
| 2005 | 7.55 Million USD | -17.91% |
| 2004 | 9.2 Million USD | 332.81% |
| 2003 | 2.12 Million USD | -31.85% |
| 2002 | 3.11 Million USD | -29.5% |
| 2001 | 4.42 Million USD | -3.95% |
| 2000 | 4.6 Million USD | -55.96% |
| 1999 | 10.46 Million USD | 45.94% |
| 1998 | 7.16 Million USD | -20.52% |
| 1997 | 9.01 Million USD | 4.92% |
| 1996 | 8.59 Million USD | 109.66% |
| 1995 | 4.1 Million USD | 0.0% |
| 1994 | 4.1 Million USD | 127.78% |
| 1993 | 1.8 Million USD | 200.0% |
| 1992 | 600 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 8.67 Million USD | -3.64% |
| 2023 Q1 | 11.91 Million USD | -4.79% |
| 2023 Q2 | 9 Million USD | -24.41% |
| 2022 Q3 | 10.92 Million USD | 62.0% |
| 2022 Q2 | 6.74 Million USD | 18.08% |
| 2022 Q1 | 5.71 Million USD | -5.12% |
| 2022 FY | 12.51 Million USD | 107.89% |
| 2022 Q4 | 12.51 Million USD | 14.55% |
| 2021 Q1 | 5.06 Million USD | -11.26% |
| 2021 Q2 | 4.84 Million USD | -4.4% |
| 2021 Q3 | 4.82 Million USD | -0.4% |
| 2021 Q4 | 6.02 Million USD | 24.75% |
| 2021 FY | 6.02 Million USD | 5.41% |
| 2020 Q1 | 5.56 Million USD | 10.66% |
| 2020 Q3 | 5.09 Million USD | -41.64% |
| 2020 FY | 5.71 Million USD | 13.5% |
| 2020 Q4 | 5.71 Million USD | 12.1% |
| 2020 Q2 | 8.72 Million USD | 56.77% |
| 2019 Q3 | 4.91 Million USD | -5.47% |
| 2019 Q1 | 4.86 Million USD | 5.51% |
| 2019 Q2 | 5.19 Million USD | 6.86% |
| 2019 FY | 5.03 Million USD | 9.13% |
| 2019 Q4 | 5.03 Million USD | 2.39% |
| 2018 Q4 | 4.61 Million USD | -35.05% |
| 2018 FY | 4.61 Million USD | -47.2% |
| 2018 Q1 | 13.37 Million USD | 53.13% |
| 2018 Q2 | 5.87 Million USD | -56.08% |
| 2018 Q3 | 7.09 Million USD | 20.86% |
| 2017 Q2 | 8.56 Million USD | -18.93% |
| 2017 Q1 | 10.56 Million USD | -86.82% |
| 2017 Q4 | 8.73 Million USD | 32.51% |
| 2017 Q3 | 6.59 Million USD | -23.02% |
| 2017 FY | 8.73 Million USD | -89.1% |
| 2016 Q2 | 72.58 Million USD | 4.53% |
| 2016 Q1 | 69.44 Million USD | 0.94% |
| 2016 Q4 | 80.12 Million USD | 6.89% |
| 2016 Q3 | 74.96 Million USD | 3.27% |
| 2016 FY | 80.12 Million USD | 16.46% |
| 2015 Q4 | 68.8 Million USD | -0.73% |
| 2015 Q1 | 46.28 Million USD | 10.92% |
| 2015 FY | 68.8 Million USD | 64.9% |
| 2015 Q2 | 66.81 Million USD | 44.37% |
| 2015 Q3 | 69.3 Million USD | 3.72% |
| 2014 Q1 | 47.24 Million USD | 6.59% |
| 2014 FY | 41.72 Million USD | -5.87% |
| 2014 Q2 | 47.42 Million USD | 0.37% |
| 2014 Q4 | 41.72 Million USD | -14.68% |
| 2014 Q3 | 48.9 Million USD | 3.12% |
| 2013 Q2 | 32.95 Million USD | 101.85% |
| 2013 Q3 | 41.07 Million USD | 24.65% |
| 2013 FY | 44.32 Million USD | 231.34% |
| 2013 Q4 | 44.32 Million USD | 7.92% |
| 2013 Q1 | 16.32 Million USD | 22.03% |
| 2012 Q3 | 10.85 Million USD | 7.61% |
| 2012 Q1 | 10.02 Million USD | -0.42% |
| 2012 Q4 | 13.37 Million USD | 23.26% |
| 2012 FY | 13.37 Million USD | 32.95% |
| 2012 Q2 | 10.08 Million USD | 0.65% |
| 2011 Q2 | 5.9 Million USD | 9.7% |
| 2011 Q4 | 10.06 Million USD | 105.59% |
| 2011 FY | 10.06 Million USD | 49.49% |
| 2011 Q1 | 5.38 Million USD | -19.96% |
| 2011 Q3 | 4.89 Million USD | -17.18% |
| 2010 Q1 | 20.3 Million USD | 7.5% |
| 2010 FY | 6.73 Million USD | -64.36% |
| 2010 Q4 | 6.73 Million USD | 14.63% |
| 2010 Q3 | 5.87 Million USD | 13.19% |
| 2010 Q2 | 5.18 Million USD | -74.45% |
| 2009 FY | 18.88 Million USD | 95.82% |
| 2009 Q1 | 24.13 Million USD | 150.19% |
| 2009 Q4 | 18.88 Million USD | -3.65% |
| 2009 Q3 | 19.6 Million USD | -47.5% |
| 2009 Q2 | 37.33 Million USD | 54.74% |
| 2008 Q1 | 8.2 Million USD | -25.41% |
| 2008 Q4 | 9.64 Million USD | 6.4% |
| 2008 Q2 | 8.56 Million USD | 4.3% |
| 2008 FY | 9.64 Million USD | -12.37% |
| 2008 Q3 | 9.06 Million USD | 5.86% |
| 2007 Q4 | 11 Million USD | 35.22% |
| 2007 FY | 11 Million USD | 32.11% |
| 2007 Q1 | 8.19 Million USD | -1.64% |
| 2007 Q2 | 8.06 Million USD | -1.57% |
| 2007 Q3 | 8.13 Million USD | 0.91% |
| 2006 Q2 | 7.21 Million USD | -1.79% |
| 2006 Q1 | 7.34 Million USD | -2.73% |
| 2006 FY | 8.33 Million USD | 10.3% |
| 2006 Q4 | 8.33 Million USD | 11.1% |
| 2006 Q3 | 7.49 Million USD | 3.93% |
| 2005 Q2 | 7.1 Million USD | 4.52% |
| 2005 Q4 | 7.55 Million USD | 8.38% |
| 2005 FY | 7.55 Million USD | -17.91% |
| 2005 Q1 | 6.8 Million USD | -26.1% |
| 2005 Q3 | 6.96 Million USD | -1.95% |
| 2004 Q3 | 1.02 Million USD | -22.5% |
| 2004 FY | 9.2 Million USD | 332.81% |
| 2004 Q1 | 1.61 Million USD | -23.96% |
| 2004 Q2 | 1.32 Million USD | -17.82% |
| 2004 Q4 | 9.2 Million USD | 793.72% |
| 2003 FY | 2.12 Million USD | -31.85% |
| 2003 Q4 | 2.12 Million USD | -33.55% |
| 2003 Q3 | 3.19 Million USD | 5.37% |
| 2003 Q2 | 3.03 Million USD | 15.46% |
| 2003 Q1 | 2.62 Million USD | -15.7% |
| 2002 Q4 | 3.11 Million USD | -40.32% |
| 2002 Q1 | 3.87 Million USD | -12.33% |
| 2002 Q2 | 4.73 Million USD | 21.94% |
| 2002 Q3 | 5.22 Million USD | 10.5% |
| 2002 FY | 3.11 Million USD | -29.5% |
| 2001 Q4 | 4.42 Million USD | 6.34% |
| 2001 Q1 | 3.98 Million USD | -13.45% |
| 2001 FY | 4.42 Million USD | -3.95% |
| 2001 Q2 | 3.84 Million USD | -3.45% |
| 2001 Q3 | 4.16 Million USD | 8.08% |
| 2000 Q3 | 4.26 Million USD | -23.55% |
| 2000 Q1 | 5.48 Million USD | -47.59% |
| 2000 FY | 4.6 Million USD | -55.96% |
| 2000 Q4 | 4.6 Million USD | 8.14% |
| 2000 Q2 | 5.57 Million USD | 1.66% |
| 1999 Q1 | 5.7 Million USD | -20.49% |
| 1999 Q3 | 9.31 Million USD | 79.04% |
| 1999 Q4 | 10.46 Million USD | 12.35% |
| 1999 FY | 10.46 Million USD | 45.94% |
| 1999 Q2 | 5.2 Million USD | -8.77% |
| 1998 Q2 | 9.4 Million USD | -10.48% |
| 1998 FY | 7.16 Million USD | -20.52% |
| 1998 Q4 | 7.16 Million USD | -18.54% |
| 1998 Q1 | 10.5 Million USD | 16.42% |
| 1998 Q3 | 8.8 Million USD | -6.38% |
| 1997 Q2 | 9.1 Million USD | 40.0% |
| 1997 Q3 | 9.7 Million USD | 6.59% |
| 1997 Q4 | 9.01 Million USD | -7.02% |
| 1997 Q1 | 6.5 Million USD | -24.38% |
| 1997 FY | 9.01 Million USD | 4.92% |
| 1996 Q4 | 8.59 Million USD | 86.87% |
| 1996 Q1 | 2.8 Million USD | -31.71% |
| 1996 Q2 | 3.1 Million USD | 10.71% |
| 1996 Q3 | 4.6 Million USD | 48.39% |
| 1996 FY | 8.59 Million USD | 109.66% |
| 1995 Q2 | 1.9 Million USD | -13.64% |
| 1995 Q4 | 4.1 Million USD | 28.13% |
| 1995 Q1 | 2.2 Million USD | -46.34% |
| 1995 FY | 4.1 Million USD | 0.0% |
| 1995 Q3 | 3.2 Million USD | 68.42% |
| 1994 FY | 4.1 Million USD | 127.78% |
| 1994 Q3 | 2.2 Million USD | 37.5% |
| 1994 Q4 | 4.1 Million USD | 86.36% |
| 1994 Q2 | 1.6 Million USD | -20.0% |
| 1994 Q1 | 2 Million USD | 11.11% |
| 1993 Q4 | 1.8 Million USD | 28.57% |
| 1993 FY | 1.8 Million USD | 200.0% |
| 1993 Q1 | 600 Thousand USD | 0.0% |
| 1993 Q2 | 700 Thousand USD | 16.67% |
| 1993 Q3 | 1.4 Million USD | 100.0% |
| 1992 FY | 600 Thousand USD | 0.0% |
| 1992 Q3 | 400 Thousand USD | 0.0% |
| 1992 Q4 | 600 Thousand USD | 50.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -36.82% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -426.722% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 91.188% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 72.23% |
| Azitra, Inc. | 2.2 Million USD | -468.255% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -234.087% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -91.332% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 31.44% |
| CEL-SCI Corporation | 17.31 Million USD | 27.715% |
| iBio, Inc. | 7.41 Million USD | -68.892% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 67.907% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -76.531% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 72.989% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -118.792% |
| NanoViricides, Inc. | 1.35 Million USD | -821.043% |
| Oragenics, Inc. | 1.79 Million USD | -595.976% |
| BiomX Inc. | 55.07 Million USD | 77.277% |
| BiomX Inc. | 55.07 Million USD | 77.277% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 75.396% |
| Palatin Technologies, Inc. | 10.85 Million USD | -15.305% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 44.973% |
| Theriva Biologics, Inc. | 20.51 Million USD | 38.993% |